title: Transport of beta-blockers and calcium antagonists by diffusion in cat myocardium.
abstract: Beta-blockers and calcium antagonists have been claimed to possess cardioprotective properties. This study addresses the question of whether a significant amount of these drugs will reach the cardiac myocytes during no-flow ischemia, where solute transport depends solely on diffusion. In anesthetized cats the hearts were excised. Apparent diffusion coefficients in cat myocardium at 37 degrees C (D'37) for 14C-verapamil (protein bound), 3H-metoprolol (lipophilic), 3H-atenolol (hydrophilic), and 3H-propranolol (lipophilic and protein bound) were determined by means of a "true transient diffusion" method and compared with the free diffusion coefficients in water (D37). D'37 of 14C-verapamil, 3H-metoprolol, 3H-atenolol, and 3H-propranolol (in cm2 s-1 10(5)) were (mean +/- SEM) 0.025 +/- 0.002, 0.055 +/- 0.003, 0.041 +/- 0.007, and 0.025 +/- 0.002, respectively. The mean diffusive progression of the concentration profile of 3H-metoprolol and 3H-atenolol into the tissue during 20 min was calculated to be 0.36 and 0.31 mm, respectively. The protein binding of 14C-verapamil and 3H-propranolol caused a significant fall in the progression to 0.24 mm for both drugs. These results indicate that, by diffusion, these drugs traverse the tissue too slowly to reach a significant amount of myocardium before myocyte necrosis occurs during conditions of noflow. Cardioprotective drugs are probably most effective, provided sufficient amounts are present in the tissue prior to the ischemic episode or sufficient supply via collateral blood flow is achieved.
authors.affiliation: Department of Medicine B, Rigshospitalet, University of Copenhagen, School of Medicine, Denmark.
authors.forename: S
authors.initials: S
authors.lastname: Haunsø
authors.forename: P
authors.initials: P
authors.lastname: Sejrsen
authors.forename: J H
authors.initials: JH
authors.lastname: Svendsen
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000493:pharmacokinetics*; D000818:Animals; D001262:Atenolol / Q000493:pharmacokinetics; D001692:Biological Transport; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics*; D002415:Cats; D004058:Diffusion; D066298:In Vitro Techniques; D008790:Metoprolol / Q000493:pharmacokinetics; D009206:Myocardium / Q000378:metabolism*; D011433:Propranolol / Q000493:pharmacokinetics; D013395:Sucrose / Q000493:pharmacokinetics; D014700:Verapamil / Q000493:pharmacokinetics
chemical_list: D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D001262:Atenolol; D013395:Sucrose; D011433:Propranolol; D014700:Verapamil; D008790:Metoprolol